Replimune Group Inc [REPL] stock prices are down -0.28% to $7.12 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Piper Sandler started tracking the stock with Overweight rating on November 19, 2021, and set its price target to $52. BTIG Research started tracking the stock assigning a Buy rating and suggested a price target of $60 on November 17, 2020. Jefferies initiated its recommendation with a Buy and recommended $67 as its price target on November 02, 2020. H.C. Wainwright upgraded its rating to Buy for this stock on October 15, 2020, and upped its price target to $54. In a note dated July 01, 2020, H.C. Wainwright downgraded an Neutral rating on this stock but restated the target price of $25.
The stock price of Replimune Group Inc [REPL] has been fluctuating between $5.89 and $24.81 over the past year. Currently, Wall Street analysts expect the stock to reach $49 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $7.12 at the most recent close of the market. An investor can expect a potential return of 588.2% based on the average REPL price forecast.
Analyzing the REPL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.39, Equity is -0.43 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.04 points at the first support level, and at 6.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.23, and for the 2nd resistance point, it is at 7.34.
Ratios To Look Out For
It’s worth pointing out that Replimune Group Inc [NASDAQ:REPL]’s Current Ratio is 12.40. As well, the Quick Ratio is 12.40, while the Cash Ratio is 2.53.
Transactions by insiders
Recent insider trading involved Xynos Konstantinos, Chief Medical Officer, that happened on Nov 16 ’23 when 7313.0 shares were sold. Chief Commercial Officer, Sarchi Christopher completed a deal on Nov 16 ’23 to sell 5255.0 shares. Meanwhile, Chief Business Officer Esposito Pamela sold 300.0 shares on Sep 12 ’23.
